Pharma channel feed

Drug­mak­ers sue HHS for try­ing to add prices to DTC ads

6 years ago
FDA+

Gene ther­a­pies seize the top of the list of the most ex­pen­sive drugs on the plan­et — and that trend has just be­gun

6 years ago
Cell/Gene Tx

J&J gains an en­thu­si­as­tic en­dorse­ment from Pres­i­dent Don­ald Trump for their big new drug Spra­va­to

6 years ago
People

An in­censed Cat­a­lyst Phar­ma sues the FDA, ac­cus­ing agency of bow­ing to po­lit­i­cal pres­sure and break­ing fed­er­al law

6 years ago
FDA+

Plagued by de­lays, As­traZeneca HQ costs soar to £750M as it edges to­ward 2020 com­ple­tion

6 years ago

Fresh analy­sis spot­lights car­dio ben­e­fit of J&J's In­vokana in di­a­betes pa­tients with­out his­to­ry of CV dis­ease

6 years ago

Sil­i­con Val­ley's most an­tic­i­pat­ed slide deck just dropped. What does it mean for bio­phar­ma's dig­i­tal teams?

6 years ago
Bioregnum
Opinion

Mer­ck grows Keytru­da in­di­ca­tions with head and neck can­cer ap­proval

6 years ago

With a sub­stan­tial dis­count to Cat­a­lyst's Fir­dapse, is Ja­cobus poised to win physi­cian, pay­er sup­port for off-la­bel adult LEMS use?

6 years ago

In a boost to Rit­ux­an fran­chise, Roche nabs quick ap­proval for po­latuzum­ab ve­dotin

6 years ago

Lil­ly's Trulic­i­ty CV out­comes da­ta un­der­whelm amid block­buster di­a­betes ri­val­ry with No­vo

6 years ago

As in­vestor con­fi­dence crum­bles fol­low­ing fund sus­pen­sion, Neil Wood­ford faces back­lash on fees

6 years ago

Once picked as a $500M win­ner, bank­rupt Achao­gen auc­tions off its an­tibi­ot­ic for a frac­tion of that

6 years ago

Fi­nan­cial­ly wob­bly opi­oid drug­mak­er In­sys agrees to pay $225M to set­tle gov­ern­ment probes

6 years ago

Cel­gene can breathe a sigh of re­lief as FDA ac­cepts once-spurned ozan­i­mod ap­pli­ca­tion — set­ting a tar­get date on a block­buster de­ci­sion

6 years ago

In­flaRx shares shat­tered as lead drug flops bad­ly in a PhI­Ib tri­al while Chemo­Cen­tryx is caught in the smash up

6 years ago
R&D

Bris­tol-My­ers bumps off chief sci­en­tist in an­oth­er big shake­up, bring­ing in Cel­gene and No­var­tis ex­ecs

6 years ago
People

The Wash­ing­ton Post points the fin­ger at Pfiz­er for stay­ing mum about an Alzheimer’s study. But there’s more to the sto­ry than that

6 years ago
Bioregnum
Opinion

Mer­ck tests an­tibi­otics wa­ters again as FDA OKs Zer­bax­a's ex­pand­ed use in pneu­mo­nia

6 years ago

#AS­CO19 roundup: As­traZeneca, Mer­ck score an­oth­er Lyn­parza hit

6 years ago
R&D

#AS­CO19: Hey Pfiz­er, No­var­tis is go­ing af­ter your block­buster can­cer fran­chise — and they have pos­i­tive OS da­ta

6 years ago
R&D

#AS­CO19: Mer­ck’s PD-1 star Keytru­da il­lus­trates just how pow­er­ful it can be over 5 years — with plen­ty of room for im­prove­ment

6 years ago
R&D

Trade war, CFIUS in­ter­ven­tions force a shift in strat­e­gy at Fo­s­un — sig­nal­ing some big po­ten­tial prob­lems for US biotechs

6 years ago
China

New Gilead chief O’Day ax­es world­wide ops chief and re­cruits Bris­tol-My­ers’ Jo­han­na Merci­er for the top team

6 years ago
People
First page Previous page 267268269270271272273 Next page Last page
A service from the Financial Times